
  
    
      
        Background_NNP
        Poisonings_NNP are_VBP among_IN the_DT most_RBS frequent_JJ indications_NNS for_IN
        hospitalization_NN in_IN the_DT United_NNP States_NNPS [_NN 1_CD ]_NN ._. However_RB ,_, the_DT
        frequency_NN of_IN hospitalizations_NNS for_IN poisonings_NNS (_( drug_NN overdose_NN
        or_CC toxicity_NN )_) in_IN renal_JJ transplant_NN recipients_NNS has_VBZ been_VBN
        infrequently_RB reported_VBN ,_, [_NN 2_CD 3_CD ]_NN in_IN contrast_NN to_TO its_PRP$
        occurrence_NN in_IN kidney_NN donors_NNS [_NN 4_CD 5_CD ]_NN ._. Because_IN many_JJ
        medications_NNS used_VBN by_IN transplant_NN recipients_NNS can_MD be_VB toxic_JJ ,_, it_PRP
        might_MD be_VB expected_VBN that_IN renal_JJ transplant_NN recipients_NNS would_MD
        have_VB a_DT higher_JJR risk_NN of_IN poisonings_NNS than_IN the_DT general_JJ
        population_NN ,_, especially_RB in_IN the_DT first_JJ post-transplant_JJ year_NN
        when_WRB dosages_NNS of_IN immunosuppressive_JJ medications_NNS are_VBP usually_RB
        at_IN their_PRP$ highest_JJS ._. Analysis_NNP of_IN the_DT incidence_NN and_CC causes_NNS of_IN
        poisonings_NNS represents_VBZ an_DT opportunity_NN to_TO explore_VB the_DT
        frequency_NN and_CC risk_NN factors_NNS for_IN medical_JJ errors_NNS ,_, since_IN many_JJ
        such_JJ complications_NNS may_MD be_VB avoidable_JJ ._. The_DT impact_NN of_IN
        hospitalized_VBN poisonings_NNS on_IN subsequent_JJ survival_NN after_IN renal_JJ
        transplantation_NN has_VBZ also_RB not_RB been_VBN assessed_VBN ._. Therefore_RB ,_, we_PRP
        analyzed_VBD national_JJ diata_NN from_IN the_DT USRDS_NNP report_NN ._. Our_PRP$
        objectives_NNS were_VBD to_TO determine_VB the_DT risk_NN factors_NNS for_IN and_CC
        mortality_NN associated_VBN with_IN hospitalized_VBN poisonings_NNS after_IN
        renal_JJ transplantation_NN ._.
      
      
        Methods_NNP
        
          Patient_NNP population_NN
          This_DT study_NN used_VBD data_NNS from_IN the_DT United_NNP States_NNPS Renal_NNP Data_NNP
          System_NNP (_( USRDS_NNP )_) ,_, using_VBG standard_JJ analysis_NN files_NNS (_( SAF_NNP 's_POS )_) as_IN
          of_IN May_NNP 2000_CD ._. The_DT variables_NNS included_VBN in_IN the_DT USRDS_NNP standard_JJ
          analysis_NN files_NNS (_( SAF_NNP 's_POS )_) ,_, as_RB well_RB as_IN data_NNS collection_NN
          methods_NNS and_CC validation_NN studies_NNS ,_, are_VBP listed_VBN at_IN the_DT USRDS_NNP
          website_NN ,_, under_IN '_POS Researcher_NNP 's_POS Guide_NNP to_TO the_DT USRDS_NNP
          Database_NNP '_POS ,_, Section_NNP E_NNP ,_, '_'' Contents_NNP of_IN all_PDT the_DT SAF_NNP 's_POS '_POS ,_,
          http_NN :_: /_NN /_NN www_NN ._. usrds_NNS ._. organd_NN published_VBN in_IN the_DT USRDS_NNP ._. The_DT
          demographics_NNS of_IN the_DT renal_JJ transplant_NN population_NN have_VBP been_VBN
          previously_RB described_VBN (_( 2001_CD USRDS_NNP report_NN )_) ._. SAF_NNP ._. TXUNOS_NNP was_VBD
          used_VBN as_IN the_DT primary_JJ dataset_NN ,_, and_CC merged_VBD with_IN variables_NNS
          from_IN SAF_NNP ._. HOSP_NNP for_IN hospitalization_NN data_NNS ,_, and_CC SAF_NNP ._. PATIENTS_NNP
          for_IN dates_NNS and_CC causes_NNS of_IN death_NN as_RB well_RB as_IN causes_NNS of_IN renal_JJ
          disease_NN ,_, as_RB previously_RB reported_VBD [_NN 6_CD 7_CD 8_CD ]_NN ._. Patient_NNP
          characteristics_NNS and_CC treatment_NN factors_NNS were_VBD those_DT at_IN the_DT
          date_NN of_IN transplant_NN ._. Recipients_NNP of_IN organs_NNS other_JJ than_IN
          kidneys_NNS were_VBD excluded_VBN ._.
        
        
          Outcome_NNP definition_NN
          We_PRP conducted_VBD an_DT historical_JJ cohort_NN study_NN of_IN the_DT
          incidence_NN ,_, risk_NN factors_NNS and_CC associated_VBN patient_NN survival_NN
          for_IN hospitalized_VBN cases_NNS of_IN poisonings_NNS (_( based_VBN on_IN
          International_NNP Classification_NNP of_IN Diseases-_NNP 9_CD th_NN Modification_NNP
          Diagnosis_NNP Codes_NNP (_( ICD_NNP 9_CD )_) 960_CD ._. x-_NN 989_CD ._. x_SYM )_) as_IN a_DT primary_JJ
          discharge_NN diagnosis_NN in_IN renal_JJ transplant_NN recipients_NNS ._. Only_RB
          the_DT primary_JJ discharge_NN diagnosis_NN was_VBD used_VBN to_TO ensure_VB these_DT
          were_VBD active_JJ diagnoses_NNS ,_, ie_NN ,_, to_TO exclude_VB diagnoses_NNS with_IN
          "_'' history_NN of_IN poisonings_NNS ._. "_'' These_DT diagnoses_NNS include_VBP
          potential_JJ overdoses_NNS for_IN heroin_NN ,_, but_CC not_RB for_IN cocaine_NN or_CC
          other_JJ illicit_JJ drugs_NNS ._. These_DT diagnoses_NNS also_RB include_VBP most_RBS
          known_VBN causes_NNS of_IN environmental_JJ exposures_NNS ,_, including_VBG
          minerals_NNS ,_, pesticides_NNS ,_, vaccinations_NNS ,_, miscellaneous_JJ
          chemicals_NNS and_CC certain_JJ foodstuffs_NNS ._. The_DT first_JJ
          hospitalization_NN for_IN poisonings_NNS after_IN the_DT first_JJ renal_JJ
          transplant_NN for_IN a_DT given_VBN individual_JJ occurring_VBG on_IN or_CC after_IN 1_CD
          July_NNP 1994_CD and_CC before_IN 1_CD July_NNP 1998_CD (_( which_WDT could_MD include_VB a_DT
          repeat_NN transplant_NN )_) ,_, with_IN followup_NN time_NN truncated_JJ at_IN three_CD
          years_NNS was_VBD counted_VBN in_IN analysis_NN ._. Hospitalizations_NNP were_VBD
          chosen_VBN because_IN they_PRP were_VBD more_RBR accessible_JJ in_IN the_DT database_NN
          and_CC less_RBR subject_JJ to_TO interpretation_NN than_IN outpatient_NN cases_NNS
          of_IN poisonings_NNS ,_, especially_RB since_IN the_DT USRDS_NNP database_NN has_VBZ no_DT
          information_NN on_IN confirmatory_NN studies_NNS ._. Hospitalization_NNP data_NNS
          for_IN transplant_NN recipients_NNS may_MD be_VB unreliable_JJ after_IN the_DT
          patient_NN has_VBZ survived_VBN â‰¥_NN 3_CD years_NNS post_NN transplant_NN ,_, when_WRB
          hospitalization_NN reporting_VBG to_TO Medicare_NNP for_IN patients_NNS 65_CD
          years_NNS or_CC younger_JJR is_VBZ no_RB longer_RB required_VBN ._. However_RB ,_, Medicare_NNP
          reporting_NN starts_VBZ immediately_RB after_IN transplant_NN ,_, regardless_RB
          of_IN preceding_VBG dialysis_NN status_NN ._. All_DT hospitalizations_NNS with_IN a_DT
          primary_JJ discharge_NN diagnosis_NN for_IN poisonings_NNS were_VBD extracted_VBN
          from_IN SAF_NNP ._. HOSP_NNP ,_, merged_VBD with_IN the_DT transplant_NN file_NN ,_, and_CC
          hospitalizations_NNS outside_IN the_DT range_NN of_IN the_DT study_NN period_NN
          were_VBD excluded_VBN ._. Hospitalizations_NNP for_IN poisonings_NNS occurring_VBG
          at_IN any_DT time_NN after_IN renal_JJ transplant_NN ,_, including_VBG after_IN graft_NN
          failure_NN (_( censored_VBN for_IN patient_NN death_NN )_) ,_, were_VBD counted_VBN in_IN
          analysis_NN ._.
        
        
          Variables_NNP used_VBD in_IN analysis_NN
          The_DT independent_JJ associations_NNS between_IN patient_NN factors_NNS
          and_CC hospitalizations_NNS for_IN poisonings_NNS were_VBD examined_VBN using_VBG
          multivariate_NN analysis_NN with_IN stepwise_NN Cox_NNP Regression_NNP
          (_( likelihood_NN ratio_NN method_NN )_) including_VBG recipient_NN and_CC donor_NN
          age_NN ,_, recipient_JJ race_NN ,_, gender_NN ,_, weight_NN ,_, pretransplant_NN
          dialysis_NN (_( yes_UH /_NN no_DT )_) ,_, year_NN of_IN transplant_NN ,_, duration_NN of_IN
          dialysis_NN prior_RB to_TO transplantation_NN ,_, total_JJ follow-up_JJ time_NN ,_,
          repeat_NN transplant_NN ,_, donor_NN cytomegalovirus_JJ serology_NN ,_,
          dialysis_NN in_IN the_DT first_JJ week_NN after_IN transplant_NN (_( delayed_VBN
          graft_NN function_NN ,_, yes_UH /_NN no_DT )_) ,_, rejection_NN (_( diagnosis_NN or_CC
          treatment_NN )_) occurring_VBG during_IN the_DT first_JJ six_CD months_NNS after_IN
          transplant_NN ,_, induction_NN antibody_NN therapy_NN ,_, maintenance_NN
          immunosuppressive_JJ medications_NNS at_IN time_NN of_IN discharge_NN after_IN
          transplant_NN surgery_NN ,_, graft_NN loss_NN (_( analyzed_VBD as_IN a_DT
          time-dependent_JJ covariate_NN as_RB previously_RB described_VBD )_) ,_, [_NN 9_CD ]_NN
          and_CC cause_NN of_IN ESRD_NNP (_( diabetes_NN ,_, systemic_JJ lupus_JJ erythematosus_JJ
          (_( because_IN of_IN the_DT potential_JJ effect_NN of_IN corticosteroid_NN
          therapy_NN prior_RB to_TO renal_JJ transplantation_NN )_) ,_, hypertension_NN and_CC
          glomerulonephritis_NNS )_) ._. Episodes_NNP of_IN rejection_NN were_VBD not_RB
          restricted_VBN to_TO those_DT occurring_VBG in_IN the_DT first_JJ year_NN ,_, in_IN
          contrast_NN to_TO studies_NNS of_IN allograft_NN function_NN ,_, since_IN there_EX is_VBZ
          no_DT evidence_NN that_IN late_JJ (_( vs_NNS ._. early_JJ )_) rejection_NN has_VBZ a_DT
          different_JJ impact_NN on_IN poisonings_NNS ._. The_DT total_JJ cumulative_JJ dose_NN
          of_IN prednisone_NN was_VBD not_RB available_JJ in_IN the_DT USRDS_NNP ._. Both_DT the_DT
          USRDS_NNP and_CC UNOS_NNP track_NN the_DT numbers_NNS of_IN days_NNS of_IN prednisone_NN
          administered_VBN prior_RB to_TO initial_JJ hospital_NN discharge_NN ,_, however_RB
          values_VBZ were_VBD missing_VBG for_IN >_NN 90_CD %_NN of_IN patients_NNS in_IN both_DT
          databases_NNS and_CC could_MD not_RB be_VB used_VBN as_IN a_DT covariate_NN in_IN the_DT
          above_JJ analyses_NNS ._. Maintenance_NNP immunosuppressive_JJ medication_NN
          use_NN at_IN the_DT time_NN of_IN discharge_NN after_IN transplantation_NN was_VBD
          also_RB analyzed_VBN as_IN a_DT preexisting_VBG covariate_NN ._. Information_NNP on_IN
          use_NN of_IN medications_NNS (_( other_JJ than_IN immunosuppressive_JJ
          medications_NNS )_) ,_, alcohol_NN ,_, tobacco_NN ,_, or_CC radiologic_JJ procedures_NNS
          was_VBD not_RB available_JJ ._.
        
        
          Survival_NNP times_NNS
          We_PRP defined_VBD patient_NN survival_NN times_NNS as_IN the_DT time_NN from_IN
          when_WRB patients_NNS had_VBD their_PRP$ first_JJ renal_JJ transplant_NN during_IN the_DT
          study_NN period_NN to_TO the_DT time_NN of_IN death_NN or_CC most_RBS recent_JJ
          follow-up_JJ date_NN (_( which_WDT was_VBD considered_VBN May_NNP 2000_CD )_) ._. For_IN time_NN
          to_TO poisonings_NNS ,_, survival_NN time_NN was_VBD defined_VBN as_IN the_DT time_NN from_IN
          first_JJ renal_JJ transplant_NN until_IN hospitalization_NN for_IN
          poisonings_NNS ,_, with_IN patients_NNS censored_VBN at_IN death_NN ,_, loss_NN to_TO
          followup_NN ,_, or_CC end_NN of_IN the_DT study_NN (_( which_WDT was_VBD considered_VBN 31_CD
          December_NNP 1999_CD ,_, since_IN this_DT was_VBD the_DT most_RBS recent_JJ
          hospitalization_NN date_NN )_) ._. The_DT patient_NN survival_NN probabilities_NNS
          were_VBD estimated_VBN by_IN using_VBG the_DT Kaplan_NNP Meier_NNP method_NN ._.
        
        
          Statistical_NNP analysis_NN
          All_DT analyses_NNS were_VBD performed_VBN using_VBG SPSS_NNP 9_CD ._. 0_CD TM_NNP (_( SPSS_NNP ,_,
          Inc_NNP ._. ,_, Chicago_NNP ,_, IL_NNP )_) ._. Files_NNP were_VBD merged_VBN and_CC converted_VBN to_TO
          SPSS_NNP files_NNS using_VBG DBMS_NNP /_NN Copy_NNP (_( Conceptual_NNP Software_NNP ,_, Houston_NNP ,_,
          TX_NNP )_) ._. Univariate_NNP analysis_NN was_VBD performed_VBN with_IN Chi-square_NNP
          testing_NN for_IN categorical_JJ variables_NNS and_CC Student_NNP 's_POS two-sided_JJ
          t-test_JJ for_IN continuous_JJ variables_NNS ._. Variables_NNP with_IN p_NN <_NN
          0_CD ._. 05_CD in_IN univariate_NN analysis_NN for_IN a_DT relationship_NN with_IN
          development_NN of_IN hospitalization_NN for_IN poisonings_NNS were_VBD
          entered_VBN into_IN multivariate_NN analysis_NN as_IN covariates_NNS ._.
          Kaplan-_NNP Meier_NNP analysis_NN was_VBD used_VBN to_TO construct_VB survival_NN
          plots_NNS of_IN time_NN to_TO hospitalized_VBN poisonings_NNS after_IN renal_JJ
          transplantation_NN ._. Log-log_NNP plots_NNS were_VBD inspected_VBN to_TO assess_VB
          for_IN proportionality_NN of_IN hazards_NNS over_IN time_NN ._. Stepwise_NNP Cox_NNP
          proportional_JJ hazards_NNS regression_NN (_( likelihood_NN ratio_NN method_NN )_)
          was_VBD used_VBN to_TO model_VB the_DT association_NN of_IN patient_NN factors_NNS with_IN
          hospitalized_VBN poisonings_NNS ._. In_IN order_NN to_TO control_VB for_IN
          misspecification_NN errors_NNS ,_, a_DT random_JJ sample_NN of_IN 25_CD %_NN of_IN
          patients_NNS was_VBD excluded_VBN from_IN analysis_NN and_CC coefficients_NNS
          estimated_VBD for_IN this_DT sample_NN ._. The_DT sample_NN was_VBD frozen_VBN ,_, and_CC
          coefficients_NNS estimated_VBD from_IN the_DT 25_CD %_NN sample_NN ._. Because_IN
          hospitalizations_NNS for_IN poisonings_NNS were_VBD uncommon_JJ ,_, Poisson_NNP
          Regression_NNP was_VBD used_VBN for_IN validation_NN ,_, using_VBG the_DT GENLOG_NNP
          approximation_NN in_IN SPSS_NNP ._. In_IN order_NN to_TO estimate_VB the_DT
          association_NN of_IN hospitalizations_NNS with_IN all-cause_JJ mortality_NN ,_,
          Cox-nonproportional_NNP hazards_NNS Regression_NNP was_VBD utilized_JJ ._.
          Times_NNS after_IN hospitalization_NN for_IN poisonings_NNS were_VBD entered_VBN
          as_IN 1_CD ,_, all_DT other_JJ times_NNS were_VBD entered_VBN as_IN 0_CD ,_, as_RB previously_RB
          described_VBD [_NN 10_CD 11_CD ]_NN ._. Patients_NNPS with_IN missing_VBG information_NN
          for_IN variables_NNS were_VBD excluded_VBN from_IN the_DT multivariate_NN models_NNS ,_,
          resulting_VBG in_IN models_NNS smaller_JJR than_IN the_DT total_JJ population_NN ._.
          Hierarchically_NNP well-formed_JJ models_NNS were_VBD used_VBN for_IN the_DT
          assessment_NN of_IN interaction_NN terms_NNS [_NN 11_CD ]_NN ._.
        
      
      
        Results_NNS
        There_EX were_VBD 42_CD ,_, 096_CD solitary_JJ renal_JJ transplant_NN recipients_NNS
        in_IN the_DT United_NNP States_NNPS Renal_NNP Data_NNP System_NNP transplanted_VBN from_IN 1_CD
        July_NNP 1994_CD to_TO 30_CD June_NNP 1998_CD ,_, of_IN whom_WP 39_CD ,_, 628_CD had_VBD complete_JJ
        enough_JJ information_NN to_TO calculate_VB survival_NN times_NNS ._. Mean_VB
        followup_NN was_VBD 1_CD ._. 89_CD Â±_NN 1_CD ._. 15_CD years_NNS (_( median_JJ ,_, 1_CD ._. 91_CD years_NNS )_) ._. Of_IN the_DT
        study_NN population_NN ,_, 170_CD recipients_NNS were_VBD hospitalized_VBN with_IN a_DT
        primary_JJ discharge_NN diagnosis_NN of_IN poisonings_NNS during_IN the_DT study_NN
        period_NN ,_, with_IN 188_CD total_JJ hospitalizations_NNS ._. The_DT cumulative_JJ
        incidence_NN of_IN hospitalizations_NNS for_IN poisonings_NNS during_IN the_DT
        study_NN period_NN was_VBD 2_CD ._. 3_CD /_NN 1000_CD person_NN years_NNS ._. Primary_JJ diagnoses_NNS
        for_IN hospitalized_VBN poisonings_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._. Suicide_NNP
        was_VBD not_RB listed_VBN as_IN an_DT eventual_JJ primary_JJ cause_NN of_IN death_NN among_IN
        patients_NNS hospitalized_VBN for_IN poisonings_NNS ,_, nor_CC was_VBD attempted_VBN
        suicide_NN (_( E_NNP 956_CD ,_, "_'' Suicide_NNP and_CC self-inflicted_JJ injuries_NNS by_IN
        cutting_VBG and_CC piercing_VBG instrument_NN ,_, "_'' or_CC E_NNP 958_CD ._. 9_CD "_'' unspecified_JJ
        cause_NN of_IN suicide_NN "_'' )_) listed_VBN as_IN a_DT secondary_JJ or_CC tertiary_JJ
        discharge_NN diagnosis_NN among_IN these_DT patients_NNS ._. The_DT mean_JJ length_NN
        of_IN stay_NN for_IN patients_NNS hospitalized_VBN for_IN poisonings_NNS was_VBD 4_CD ._. 05_CD Â±_NN
        4_CD ._. 15_CD days_NNS (_( range_NN ,_, 1_CD -_: 41_CD days_NNS )_) ._. Among_IN renal_JJ transplant_NN
        recipients_NNS with_IN diabetes_NN ,_, the_DT most_RBS common_JJ cause_NN of_IN
        hospitalized_VBN poisonings_NNS was_VBD insulin_NN /_NN antidiabetic_JJ agents_NNS ,_,
        while_IN in_IN patients_NNS who_WP experienced_VBD allograft_NN rejection_NN ,_, the_DT
        most_RBS common_JJ cause_NN of_IN hospitalized_VBN poisonings_NNS was_VBD
        immunosuppressive_JJ agents_NNS ._.
        The_DT time_NN to_TO hospitalization_NN for_IN poisonings_NNS is_VBZ shown_VBN in_IN
        Figure_NN 1_CD ._. As_IN shown_VBN ,_, the_DT risk_NN of_IN hospitalized_VBN poisonings_NNS
        were_VBD highest_JJS in_IN the_DT first_JJ few_JJ months_NNS after_IN renal_JJ
        transplantation_NN ,_, with_IN a_DT consistent_JJ risk_NN afterward_RB ._. Figures_NNS
        2_CD and_CC 3_CD show_NN the_DT time_NN to_TO hospitalization_NN for_IN poisoning_NN
        stratified_JJ by_IN allograft_NN rejection_NN and_CC body_NN mass_NN index_NN ,_,
        respectively_RB ._. In_IN Figure_NN 2_CD ,_, analysis_NN was_VBD limited_VBN to_TO patients_NNS
        who_WP survived_VBD at_IN least_JJS 6_CD months_NNS after_IN transplant_NN ._. In_IN figure_NN
        3_CD ,_, the_DT risk_NN of_IN poisonings_NNS for_IN all_DT transplant_NN recipients_NNS was_VBD
        similar_JJ for_IN the_DT first_JJ six_CD months_NNS by_IN both_DT survival_NN plots_NNS and_CC
        log-log_JJ plots_NNS ._. Therefore_RB ,_, since_IN this_DT violated_VBN the_DT
        proportional_JJ hazards_NNS assumption_NN ,_, multivariate_NN analysis_NN was_VBD
        also_RB performed_VBN limited_VBN to_TO patients_NNS who_WP survived_VBD at_IN least_JJS
        six_CD months_NNS after_IN transplant_NN ._.
        Characteristics_NNP of_IN the_DT study_NN population_NN ,_, including_VBG
        results_NNS of_IN both_DT univariate_NN and_CC multivariate_NN analysis_NN ,_, are_VBP
        shown_VBN in_IN table_NN 2_CD (_( see_VB additional_JJ file_NN 1_LS )_) ._. In_IN univariate_NN
        analysis_NN ,_, factors_NNS associated_VBN with_IN an_DT increased_VBN risk_NN of_IN
        hospitalized_VBN poisonings_NNS were_VBD low_JJ body_NN mass_NN index_NN ,_, graft_NN
        loss_NN ,_, cadaveric_JJ donor_NN ,_, rejection_NN within_IN 6_CD months_NNS after_IN
        transplant_NN ,_, and_CC diabetes_NN ,_, while_IN male_JJ gender_NN was_VBD associated_VBN
        with_IN reduced_VBN risk_NN of_IN poisoning_NN ._. In_IN Cox_NNP Regression_NNP analysis_NN ,_,
        however_RB ,_, the_DT only_RB two_CD factors_NNS independently_RB associated_VBN with_IN
        hospitalized_VBN poisoning_NN were_VBD low_JJ body_NN mass_NN index_NN and_CC
        allograft_NN rejection_NN ._. There_EX were_VBD no_DT significant_JJ interactions_NNS
        between_IN covariates_NNS ,_, specifically_RB no_DT interactions_NNS between_IN
        maintenance_NN or_CC induction_NN medications_NNS ,_, or_CC between_IN age_NN and_CC
        body_NN mass_NN index_NN ._. In_IN analysis_NN limited_VBN to_TO recipients_NNS age_NN 18_CD
        and_CC over_IN ,_, low_JJ body_NN mass_NN index_NN (_( as_IN assessed_VBN in_IN Table_NNP 3_CD ,_, AHR_NNP ,_,
        2_CD ._. 74_CD ,_, 95_CD %_NN CI_NNP ,_, 1_CD ._. 29_CD -_: 5_CD ._. 82_CD ,_, p_NN =_SYM 0_CD ._. 009_CD )_) and_CC rejection_NN (_( AHR_NNP ,_,
        1_CD ._. 88_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 16_CD -_: 3_CD ._. 05_CD ,_, p_NN =_SYM 0_CD ._. 01_CD )_) were_VBD again_RB the_DT only_JJ
        factors_VBZ significantly_RB associated_VBN with_IN hospitalized_VBN
        poisonings_NNS ._.
        Additional_JJ file_NN 1_CD
        Table_NNP 2_CD
        Click_NNP here_RB for_IN file_NN
        Mortality_NNP after_IN hospitalizations_NNS for_IN poisoning_NN ,_, which_WDT
        was_VBD constant_JJ over_IN time_NN ,_, is_VBZ shown_VBN in_IN Figure_NN 4_CD ._.
        Hospitalizations_NNP for_IN poisonings_NNS were_VBD independently_RB
        associated_VBN with_IN increased_VBN mortality_NN in_IN Cox_NNP Regression_NNP (_( AHR_NNP ,_,
        1_CD ._. 54_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 22_CD -_: 1_CD ._. 92_CD ,_, p_NN =_SYM 0_CD ._. 002_CD )_) ._.
      
      
        Discussion_NNP
        The_DT present_JJ study_NN demonstrated_VBN that_IN almost_RB all_DT
        hospitalizations_NNS for_IN poisonings_NNS after_IN renal_JJ transplantation_NN
        were_VBD due_JJ to_TO the_DT use_NN of_IN prescription_NN medications_NNS ,_, even_RB
        though_IN ICD_NNP 9_CD codes_NNS 960_CD -_: 989_CD ._. x_SYM also_RB include_VBP poisonings_NNS from_IN
        environmental_JJ toxins_NNS ,_, vaccines_NNS ,_, and_CC anesthetic_JJ agents_NNS ._.
        Because_IN many_JJ immunosuppressive_JJ medications_NNS are_VBP toxic_JJ ,_, this_DT
        was_VBD not_RB a_DT surprising_JJ finding_NN ._. However_RB ,_, reports_NNS from_IN the_DT
        medical_JJ literature_NN have_VBP been_VBN infrequent_JJ ,_, as_IN indicated_VBN
        previously_RB ._. In_IN fact_NN ,_, a_DT Medline_NNP search_NN for_IN the_DT terms_NNS
        "_'' medication_NN error_NN transplant_NN "_'' yielded_VBD only_RB 14_CD papers_NNS ,_, [_NN 12_CD
        13_CD ]_NN and_CC none_NN was_VBD returned_VBN for_IN the_DT search_NN "_'' medication_NN error_NN
        renal_JJ transplant_NN ._. "_'' Therefore_RB ,_, review_NN of_IN the_DT medical_JJ
        literature_NN might_MD give_VB a_DT misleading_JJ indication_NN of_IN the_DT
        frequency_NN of_IN this_DT complication_NN ._. Although_IN reported_VBD
        hospitalizations_NNS for_IN poisonings_NNS as_IN a_DT primary_JJ diagnosis_NN were_VBD
        not_RB common_JJ ,_, hospitalizations_NNS for_IN poisonings_NNS were_VBD
        independently_RB associated_VBN with_IN increased_VBN mortality_NN in_IN renal_JJ
        transplant_NN recipients_NNS ,_, and_CC also_RB represented_VBD potentially_RB
        avoidable_JJ morbidity_NN with_IN a_DT mean_JJ length_NN of_IN stay_NN of_IN over_IN 4_CD
        days_NNS ._.
        Anti-neoplastic_NNP /_NN immunosuppressive_JJ agents_NNS were_VBD the_DT most_RBS
        common_JJ cause_NN of_IN poisonings_NNS in_IN this_DT population_NN ,_, as_IN would_MD be_VB
        expected_VBN ._. The_DT current_JJ study_NN almost_RB certainly_RB underestimates_NNS
        the_DT incidence_NN of_IN serious_JJ immunosuppressive_JJ drug_NN toxicity_NN in_IN
        this_DT population_NN ._. In_IN addition_NN ,_, renal_JJ transplant_NN recipients_NNS
        have_VBP many_JJ potential_JJ indications_NNS for_IN the_DT use_NN of_IN
        analgesics_NNS /_NN antipyretics_NNS ,_, post-operative_JJ pain_NN among_IN them_PRP [_NN
        14_CD ]_NN ._. The_DT frequent_JJ occurrence_NN of_IN poisonings_NNS due_JJ to_TO
        analgesics_NNS after_IN renal_JJ transplantation_NN may_MD therefore_RB seem_VB
        understandable_JJ ._. However_RB ,_, although_IN the_DT risk_NN of_IN poisonings_NNS
        was_VBD highest_JJS in_IN the_DT first_JJ few_JJ months_NNS after_IN transplantation_NN ,_,
        the_DT increase_NN in_IN relative_JJ risk_NN in_IN this_DT time_NN was_VBD not_RB visually_RB
        remarkable_JJ (_( Figure_NN 1_LS )_) ,_, and_CC the_DT risk_NN of_IN poisoning_NN continued_VBD
        in_IN a_DT constant_JJ fashion_NN after_IN transplant_NN ._. There_EX was_VBD certainly_RB
        no_DT early_JJ peak_NN followed_VBN by_IN a_DT dramatic_JJ stabilization_NN in_IN rates_NNS
        of_IN poisonings_NNS ,_, as_IN has_VBZ been_VBN demonstrated_VBN for_IN
        hospitalizations_NNS for_IN cytomegalovirus_JJ disease_NN ,_, [_NN 15_CD ]_NN
        contrary_JJ to_TO what_WP might_MD have_VB been_VBN expected_VBN ._. This_DT suggests_VBZ
        the_DT possibility_NN that_IN either_DT the_DT dosing_VBG or_CC use_NN of_IN these_DT
        medications_NNS may_MD not_RB be_VB adjusted_VBN optimally_RB after_IN renal_JJ
        transplantation_NN ._.
        Benzodiazepines_NNP /_NN tranquilizers_NNS were_VBD the_DT third_JJ most_RBS common_JJ
        cause_NN of_IN poisonings_NNS in_IN this_DT study_NN ._. It_PRP is_VBZ noteworthy_JJ that_DT
        calcineurin_NN inhibitor_NN toxicity_NN may_MD mimic_VB anxiety_NN or_CC
        nervousness_NN ,_, [_NN 16_CD ]_NN which_WDT are_VBP common_JJ indications_NNS for_IN the_DT
        use_NN of_IN benzodiazepines_NNS ._. In_IN addition_NN ,_, many_JJ antidepressive_JJ
        agents_NNS may_MD raise_VB levels_NNS of_IN calcineurin_NN inhibitors_NNS [_NN 17_CD ]_NN ._.
        Results_NNS of_IN the_DT present_JJ study_NN raise_VBP the_DT possibility_NN that_IN
        indications_NNS for_IN treatment_NN with_IN benzodiazepines_NNS may_MD actually_RB
        represent_VB toxicities_NNS of_IN calcineurin_NN antagonists_NNS ,_, which_WDT
        might_MD be_VB best_RBS managed_VBN by_IN adjusting_VBG the_DT dose_NN of_IN the_DT
        calcineurin_NN inhibitors_NNS ._. Until_IN then_RB ,_, we_PRP would_MD suggest_VB that_IN
        the_DT possibility_NN of_IN other_JJ drug_NN toxicities_NNS ,_, including_VBG drug_NN
        interactions_NNS ,_, be_VB thoroughly_RB excluded_VBN before_IN prescribing_VBG
        benzodiazepines_NNS in_IN this_DT population_NN ._. Often_RB overlooked_VBD is_VBZ the_DT
        effect_NN of_IN erratic_JJ compliance_NN with_IN azole_NN antifungals_NNS ,_,
        anticonvulsants_NNS or_CC other_JJ medications_NNS that_WDT inhibit_VBP or_CC induce_VB
        calcineurin_NN inhibitors_NNS ._.
        The_DT high_JJ frequency_NN of_IN poisonings_NNS due_JJ to_TO
        insulin_NN /_NN antidiabetic_JJ agents_NNS is_VBZ also_RB not_RB surprising_VBG given_VBN
        the_DT high_JJ frequency_NN of_IN diabetes_NN among_IN renal_JJ transplant_NN
        recipients_NNS ,_, although_IN diabetes_NN was_VBD not_RB an_DT independent_JJ risk_NN
        factor_NN for_IN poisonings_NNS in_IN the_DT present_JJ analysis_NN ._. This_DT
        suggests_VBZ that_IN diabetic_JJ transplant_NN recipients_NNS should_MD be_VB
        monitored_VBN with_IN particularly_RB close_JJ attention_NN ,_, perhaps_RB in_IN
        concert_NN with_IN regular_JJ visits_NNS with_IN a_DT pharmacist_NN [_NN 18_CD ]_NN or_CC as_IN
        part_NN of_IN a_DT disease_NN management_NN program_NN to_TO reduce_VB medical_JJ
        errors_NNS [_NN 19_CD ]_NN ._.
        Considering_VBG that_IN almost_RB all_DT causes_NNS of_IN hospitalized_VBN
        poisonings_NNS after_IN renal_JJ transplantation_NN were_VBD attributed_VBN to_TO
        prescription_NN medications_NNS ,_, the_DT risk_NN factors_NNS for_IN hospitalized_VBN
        poisonings_NNS in_IN the_DT present_JJ study_NN ,_, namely_RB allograft_NN rejection_NN
        and_CC low_JJ body_NN mass_NN index_NN ,_, are_VBP all_PDT the_DT more_RBR remarkable_JJ ._. The_DT
        significance_NN of_IN a_DT low_JJ body_NN mass_NN index_NN as_IN an_DT independent_JJ
        risk_NN factor_NN for_IN poisonings_NNS in_IN this_DT analysis_NN as_IN a_DT risk_NN
        factor_NN for_IN hospitalized_VBN poisonings_NNS ,_, independent_JJ of_IN age_NN ,_,
        suggests_VBZ the_DT possibility_NN of_IN suboptimal_NN dose_NN adjustment_NN of_IN
        medications_NNS ._. This_DT particularly_RB applies_VBZ to_TO calcineurin_NN
        inhibitors_NNS ,_, which_WDT are_VBP lipid_NN soluble_JJ and_CC have_VBP a_DT large_JJ volume_NN
        of_IN distribution_NN ._. Most_JJS calcineurin_NN inhibitors_NNS are_VBP initiated_VBN
        adjusted_VBN for_IN patient_NN weight_NN ._. However_RB ,_, in_IN a_DT small_JJ percentage_NN
        of_IN patients_NNS currently_RB recommended_VBD doses_NNS may_MD still_RB result_VB in_IN
        toxicity_NN ._. Area-under-the-curve_NNP monitoring_VBG gives_VBZ an_DT estimate_NN
        of_IN total_JJ drug_NN exposure_NN and_CC may_MD help_VB minimize_VB toxicity_NN ,_,
        particularly_RB in_IN patients_NNS with_IN unusual_JJ clinical_JJ responses_NNS to_TO
        standard_JJ dosing_VBG [_NN 20_CD ]_NN ._. It_PRP would_MD be_VB useful_JJ to_TO test_VB this_DT
        hypothesis_NNS in_IN future_JJ studies_NNS ._.
        The_DT association_NN of_IN poisonings_NNS with_IN allograft_NN rejection_NN
        in_IN this_DT category_NN of_IN patients_NNS may_MD represent_VB toxicity_NN due_JJ to_TO
        bolus_JJ intravenous_JJ or_CC high_JJ dose_NN oral_JJ corticosteroid_NN therapy_NN ,_,
        or_CC significant_JJ drug-drug_JJ interactions_NNS in_IN this_DT setting_NN ,_,
        which_WDT the_DT database_NN could_MD not_RB determine_VB ._. However_RB ,_, the_DT
        findings_NNS of_IN the_DT present_JJ analysis_NN suggest_VBP a_DT need_NN for_IN
        providers_NNS nationally_RB to_TO reevaluate_NN the_DT use_NN of_IN
        immunosuppressive_JJ agents_NNS in_IN a_DT systematic_JJ fashion_NN after_IN
        transplantation_NN ._. The_DT management_NN of_IN renal_JJ transplant_NN
        patients_NNS is_VBZ certainly_RB not_RB uniform_NN ;_: in_IN some_DT centers_NNS ,_, the_DT
        primary_JJ transplant_NN surgeon_NN may_MD continue_VB management_NN of_IN the_DT
        patient_NN up_IN to_TO a_DT year_NN or_CC more_JJR after_IN transplant_NN ,_, while_IN in_IN
        other_JJ centers_VBZ a_DT nephrologist_NN or_CC even_RB primary_JJ care_NN physician_NN
        may_MD assume_VB primary_JJ management_NN of_IN the_DT patient_NN after_IN the_DT
        first_JJ transplant_NN month_NN ._. It_PRP is_VBZ possible_JJ that_IN more_RBR
        standardized_JJ guidance_NN on_IN dosing_VBG and_CC the_DT possibility_NN of_IN drug_NN
        interactions_NNS would_MD be_VB beneficial_JJ ._. Currently_RB ,_, there_EX are_VBP no_DT
        clinical_JJ practice_NN guidelines_NNS on_IN the_DT dosing_VBG of_IN transplant_NN
        related_VBD medications_NNS ,_, although_IN certain_JJ institutional_JJ
        guidelines_NNS do_VBP exist_VB [_NN 21_CD ]_NN ._.
        The_DT present_JJ study_NN is_VBZ limited_VBN by_IN use_NN of_IN primary_JJ
        hospitalization_NN diagnoses_NNS for_IN outcomes_NNS ._. The_DT true_JJ frequency_NN
        of_IN poisonings_NNS and_CC medication_NN errors_NNS in_IN the_DT renal_JJ transplant_NN
        population_NN is_VBZ most_RBS likely_RB underestimated_VBN ._. Because_IN of_IN the_DT
        study_NN 's_POS retrospective_NN nature_NN ,_, many_JJ other_JJ factors_NNS could_MD not_RB
        be_VB validated_JJ ._. Patients_NNS with_IN multiple_JJ potential_JJ causes_NNS for_IN
        admission_NN may_MD not_RB have_VB been_VBN included_VBN among_IN patients_NNS with_IN
        hospitalized_VBN poisonings_NNS ._. However_RB ,_, the_DT study_NN is_VBZ population_NN
        based_VBD ,_, and_CC because_IN accurate_JJ coding_VBG for_IN hospitalization_NN
        discharge_NN is_VBZ required_VBN ,_, is_VBZ likely_JJ to_TO be_VB less_RBR subject_JJ to_TO
        reporting_VBG bias_NN than_IN case_NN reports_NNS of_IN poisonings_NNS in_IN the_DT
        medical_JJ literature_NN ._.
        The_DT present_JJ study_NN could_MD not_RB determine_VB the_DT reason_NN for_IN
        poisonings_NNS ._. In_IN short_JJ ,_, the_DT possibilities_NNS of_IN patient_NN error_NN
        vs_NNS ._. provider_NN error_NN could_MD not_RB be_VB distinguished_VBN ._. However_RB ,_,
        consultation_NN with_IN pharmacists_NNS may_MD reduce_VB both_DT [_NN 22_CD ]_NN ._.
        Given_VBN the_DT looming_VBG shortage_NN of_IN nephrologists_NNS ,_, [_NN 23_CD ]_NN nurses_NNS ,_,
        and_CC other_JJ medical_JJ providers_NNS ,_, [_NN 24_CD ]_NN multiple_JJ safeguards_NNS
        need_VBP to_TO be_VB established_VBN to_TO minimize_VB the_DT possibility_NN of_IN error_NN
        as_RB much_RB as_IN possible_JJ in_IN these_DT complex_JJ and_CC challenging_VBG
        patients_NNS ._. This_DT is_VBZ particularly_RB true_JJ given_VBN the_DT significant_JJ
        associations_NNS of_IN both_DT body_NN mass_NN index_NN and_CC allograft_NN
        rejection_NN with_IN hospitalized_VBN poisonings_NNS in_IN this_DT analysis_NN ,_,
        which_WDT may_MD indicate_VB that_IN more_RBR complex_JJ and_CC individualized_JJ
        methods_NNS of_IN medication_NN dosing_VBG may_MD be_VB necessary_JJ after_IN renal_JJ
        transplantation_NN than_IN are_VBP currently_RB used_VBN ._. The_DT present_JJ study_NN
        identifies_VBZ specific_JJ targets_NNS for_IN investigation_NN and_CC
        improvement_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Kevin_NNP C_NNP ._. Abbott_NNP conceived_VBD the_DT study_NN ,_, conducted_VBD all_DT
        analysis_NN and_CC wrote_VBD most_JJS of_IN the_DT manuscript_NN ._. Rebecca_NNP Viola_NNP
        advised_VBD on_IN toxic_JJ effects_NNS of_IN drugs_NNS ,_, and_CC wrote_VBD substantial_JJ
        amounts_NNS of_IN the_DT discussion_NN ._. Lawrence_NNP Agodoa_NNP is_VBZ Project_NNP
        Director_NNP of_IN the_DT NIDDK_NNP and_CC supervised_VBD all_DT aspects_NNS of_IN the_DT
        manuscript_NN ._.
      
    
  
